A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
Status:
Completed
Trial end date:
2009-02-05
Target enrollment:
Participant gender:
Summary
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly
to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or
liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was
double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy
parameter was HbA1c and the treatment duration was 12 weeks.